Eprontia
Generic name: Topiramate
Dosage form: oral solution
Drug class:
Carbonic anhydrase inhibitor anticonvulsants
Usage of Eprontia
Eprontia is a prescription medicine used:
Eprontia side effects
Eprontia may cause serious side effects including: See Important information
Call your healthcare provider right away if you have any of the symptoms above. The most common side effects include:
Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of Eprontia. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Azurity Pharmaceuticals, Inc. at 1-855-379-0383.
Before taking Eprontia
Before taking Eprontia, tell your healthcare provider about all of your medical conditions, including if you:
Relate drugs
- Eprontia
- Qudexy XR
- Qudexy XR Sprinkle
- Topamax
- Topamax Sprinkle
- Topiragen
- Topiramate
- Topiramate ER (Eqv-Qudexy XR)
- Trokendi XR
- Zonegran
- Zonisade
- Zonisamide
How to use Eprontia
Usual dose for Epilepsy Monotherapy in Adults and Pediatric Patients (10 years of age and older)
The recommended dose for Eprontia monotherapy in adults and pediatric patients 10 years of age and older is 400 mg/day in two divided doses. The dose should be achieved by titration according to the following schedule:
Morning Dose Evening Dose Week 1 25 mg 25 mg Week 2 50 mg 50 mg Week 3 75 mg 75 mg Week 4 100 mg 100 mg Week 5 150 mg 150 mg Week 6 200 mg 200 mgUsual dose for Epilepsy Monotherapy in Pediatric Patients (2 to 9 Years of Age)
Dosing in patients 2 to 9 years of age is based on weight. During the titration period, the initial dose of Eprontia is 25 mg/day nightly for the first week. Based upon tolerability, the dosage can be increased to 50 mg/day (25 mg twice daily) in the second week. Dosage can be increased by 25–50 mg/day each subsequent week as tolerated. Titration to the minimum maintenance dose should be attempted over 5–7 weeks of the total titration period. Based upon tolerability and clinical response, additional titration to a higher dose (up to the maximum maintenance dose) can be attempted at 25–50 mg/day weekly increments. The total daily dose should not exceed the maximum maintenance dose for each range of body weight.
Weight (kg) Total Daily Dose (mg/day)* Minimum Maintenance Dose Total Daily Dose (mg/day)* Maximum Maintenance Dose Up to 11 150 250 12-22 200 300 23-31 200 350 32-38 250 350 Greater than 38 250 400* Administered in two equally divided doses
Usual dose for Epilepsy Adjunctive Therapy in Adults (17 Years of Age and Older)
The recommended total daily dose of Eprontia as adjunctive therapy in adults with partial onset seizures or Lennox-Gastaut Syndrome is 200 to 400 mg/day in two divided doses, and 400 mg/day in two divided doses as adjunctive treatment in adults with primary generalized tonic-clonic seizures. Eprontia should be initiated at 25 to 50 mg/day, followed by titration to an effective dose in increments of 25 to 50 mg/day every week. Titrating in increments of 25 mg/day every week may delay the time to reach an effective dose. Doses above 400 mg/day have not been shown to improve responses in adults with partial-onset seizures.
Usual dose for Epilepsy Adjunctive Therapy in Pediatric Patients (2 to 16 Years of Age)
The recommended total daily dose of Eprontia as adjunctive therapy for pediatric patients 2 to 16 years of age with partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome is approximately 5 to 9 mg/kg/day in two divided doses. Titration should begin at 25 mg/day (or less, based on a range of 1 to 3 mg/kg/day) nightly for the first week. The dosage should then be increased at 1- or 2-week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response. Dose titration should be guided by clinical outcome. The total daily dose should not exceed 400 mg/day.
Usual dose for Preventive Treatment of Migraine
The recommended total daily dose of Eprontia as treatment for patients 12 years of age and older for the preventive treatment of migraine is 100 mg/day administered in two divided doses. The recommended titration rate for Eprontia for the preventive treatment of migraine is as follows:
Morning Dose Evening Dose Week 1 None 25 mg Week 2 25 mg 25 mg Week 3 25 mg 50 mg Week 4 50 mg 50 mgDose and titration rate should be guided by clinical outcome. If required, longer intervals between dose adjustments can be used.
Warnings
Eprontia may cause eye problems. Serious eye problems include:
Eprontia may cause decreased sweating and increased body temperature (fever). People, especially children, should be watched for signs of decreased sweating and fever, especially in hot temperatures. Some people may need to be hospitalized for this condition. If a high fever, a fever that does not go away, or decreased sweating develops, call your healthcare provider right away. Eprontia can increase the level of acid in your blood (metabolic acidosis). If left untreated, metabolic acidosis can cause brittle or soft bones (osteoporosis, osteomalacia, osteopenia), kidney stones, can slow the rate of growth in children, and may possibly harm your baby if you are pregnant. Metabolic acidosis can happen with or without symptoms. Sometimes people with metabolic acidosis will:
Your healthcare provider should do a blood test to measure the level of acid in your blood before and during your treatment with Eprontia. If you are pregnant, you should talk to your healthcare provider about whether you have metabolic acidosis. Like other antiepileptic drugs, Eprontia may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you:
Do not stop Eprontia without first talking to a healthcare provider.
How can I watch for early symptoms of suicidal thoughts and actions?
Eprontia can harm your unborn baby.
Pregnancy Registry: If you become pregnant while taking Eprontia, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by calling 1-888-233-2334. The purpose of this registry is to collect information about the safety of Eprontia and other antiepileptic drugs during pregnancy.
What other drugs will affect Eprontia
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Eprontia and other medicines may affect each other causing side effects.
Especially tell your healthcare provider if you take:
Ask your healthcare provider if you are not sure if your medicine is listed above.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist each time you get a new medicine. Do not start a new medicine without talking with your healthcare provider.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions